高治疗后血清 CA-125 水平的晚期卵巢癌患者中延长化疗的作用。

Role of extended chemotherapy in advanced ovarian cancer patients with high posttreatment serum CA-125 levels.

机构信息

Branch of Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South Korea.

出版信息

Gynecol Obstet Invest. 2011;72(1):50-4. doi: 10.1159/000322438. Epub 2011 Mar 3.

DOI:10.1159/000322438

PMID:21372548

Abstract

BACKGROUND

We aimed to determine whether the inclusion of additional cycles of carboplatin-paclitaxel is beneficial to patients with high posttreatment serum CA-125 levels.

METHODS

Among patients who achieved remission after six cycles of carboplatin-paclitaxel chemotherapy, those with CA-125 of 10-35 U/ml at the time of remission were divided into two groups (group A: six cycles of standard chemotherapy vs. group B: two or more additional cycles) and were analyzed.

RESULTS

Among the 436 patients with advanced epithelial ovarian cancer, 154 patients (46.8%) had CA-125 of 10-35 U/ml at the time of remission. Fifty-six patients (36.4%) received two or more cycles after the first six cycles of chemotherapy (group B). The addition of two or more cycles of chemotherapy did not improve the progression-free survival (p = 0.660). There was no statistical difference in the rates of CA-125 falling to <10 U/ml between the two groups (p = 0.256). Moreover, the degree of CA-125 decrease after six cycles of chemotherapy was similar regardless of the additional cycles (p = 0.656).

CONCLUSION

The addition of two or more cycles of standard chemotherapy based on posttreatment CA-125 levels was not beneficial.

摘要

背景

我们旨在确定在治疗后血清 CA-125 水平较高的患者中，增加卡铂紫杉醇周期是否有益。

方法

在接受六周期卡铂紫杉醇化疗后达到缓解的患者中，将 CA-125 在缓解时为 10-35 U/ml 的患者分为两组（A 组：六周期标准化疗与 B 组：两个或更多附加周期）进行分析。

结果

在 436 例晚期上皮性卵巢癌患者中，有 154 例（46.8%）在缓解时 CA-125 为 10-35 U/ml。56 例（36.4%）在第一六周期化疗后接受了两个或更多周期化疗（B 组）。添加两个或更多周期的化疗并不能改善无进展生存期（p=0.660）。两组 CA-125 降至<10 U/ml 的比率无统计学差异（p=0.256）。此外，无论附加周期如何，六周期化疗后 CA-125 的降低程度相似（p=0.656）。